Cho, Nicholas S.
Sanvito, Francesco
Thakuria, Shruti
Wang, Chencai
Hagiwara, Akifumi
Nagaraj, Raksha
Oshima, Sonoko
Lopez Kolkovsky, Alfredo L.
Lu, Jianwen
Raymond, Catalina
Liau, Linda M.
Everson, Richard G.
Patel, Kunal S.
Kim, Won
Yang, Isaac
Bergsneider, Marvin
Nghiemphu, Phioanh L.
Lai, Albert
Nathanson, David A.
Cloughesy, Timothy F.
Ellingson, Benjamin M.
Funding for this research was provided by:
National Institutes of Health (T32GM008042, P50CA211015, R01CA270027)
U.S. Department of Defense (CA20029)
Article History
Received: 10 May 2023
Accepted: 2 June 2023
First Online: 9 June 2023
Declarations
:
: BME is on the advisory board and is a paid consultant for Medicenna, MedQIA, Servier Pharmaceuticals, Siemens, Janssen Pharmaceuticals, Imaging Endpoints, Kazia, Oncoceutics/Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Neosoma, Alpheus Medical, Sagimet Biosciences, Sapience Therapeutics , and the Global Coalition for Adaptive Research (GCAR). TFC is cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, holds stock for Erasca, member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research, holds stock in Chimerix and receives milestone payments and possible future royalties, member of the scientific advisory board for Break Through Cancer, member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to Blue Rock, Vida Ventures, Lista Therapeutics, Stemline, Novartis, Roche, Sonalasense, Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Novocure, Novogen, Boston Biomedical, Sunovion, Insys, Pfizer, Notable labs, Medqia, Trizel, Medscape and has contracts with UCLA for the Brain Tumor Program with Roche, VBI, Merck, Novartis, BMS, AstraZeneca, Servier. The Regents of the University of California (T.F.C. employer) has licensed intellectual property co-invented by TFC to Katmai Pharmaceuticals. DAN is a co-founder, major stockholder, consultant and board member of Katmai Pharmaceuticals, holds stock for Erasca which has licensed intellectual property related to ERAS-801, and have equity in the company; a co-founder of Trethera Corporation and has equity in the company; and has equity in Sofie Biosciences. PLN has received grants/contracts from ERASCA, Millenium, Children’s Tumor Foundation, Dept of Defense, GCAR, Springsworks, and BMS and has received payment/honoraria from Alexion.
: A portion of the results were presented at the Society for Neuro-Oncology 2022 Annual Meeting.
: This study was performed in compliance with the Health Insurance Portability and Accountability Act. This study was approved by our institutional review board (IRB# 21–000514). All patients provided written informed consent.